APLS vs. RDY, VTRS, ASND, PCVX, QGEN, ROIV, SRPT, RVMD, BBIO, and LNTH
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Ascendis Pharma A/S (ASND), Vaxcyte (PCVX), Qiagen (QGEN), Roivant Sciences (ROIV), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.
Apellis Pharmaceuticals vs.
Dr. Reddy's Laboratories (NYSE:RDY) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.
Dr. Reddy's Laboratories has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.
Dr. Reddy's Laboratories has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
Dr. Reddy's Laboratories currently has a consensus target price of $17.00, suggesting a potential upside of 29.39%. Apellis Pharmaceuticals has a consensus target price of $45.53, suggesting a potential upside of 107.16%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.
In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 7 articles in the media. Dr. Reddy's Laboratories' average media sentiment score of 1.18 beat Apellis Pharmaceuticals' score of 0.69 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.
3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Dr. Reddy's Laboratories has a net margin of 17.25% compared to Apellis Pharmaceuticals' net margin of -34.97%. Dr. Reddy's Laboratories' return on equity of 17.87% beat Apellis Pharmaceuticals' return on equity.
Apellis Pharmaceuticals received 26 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 66.99% of users gave Apellis Pharmaceuticals an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote.
Summary
Apellis Pharmaceuticals beats Dr. Reddy's Laboratories on 10 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:APLS) was last updated on 3/31/2025 by MarketBeat.com Staff
